Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, KRYS, CELC, NVCR, PRAX, and represent 36.27% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$213M), DXCM (+$86M), CELC (+$63M), GMED (+$62M), PODD (+$43M), ALKS (+$37M), LIVN (+$35M), MIRM (+$34M), IMVT (+$28M), PCVX (+$28M).
- Started 32 new stock positions in PODD, EWTX, TFX, ABVX, IVVD, IMVT, CAPR, PCVX, ORKA, DYN.
- Reduced shares in these 10 stocks: TERN (-$320M), PRAX (-$146M), CDTX (-$101M), ELV (-$84M), Indivior (-$49M), UTHR (-$44M), BBNX (-$41M), INSP (-$40M), MDGL (-$40M), ARGX (-$32M).
- Sold out of its positions in ADMA, ADVM, AKRO, ELV, CBLL, EPIX, ETON, GRFS, HROW, IDYA.
- Soleus Capital Management was a net seller of stock by $-257M.
- Soleus Capital Management has $2.7B in assets under management (AUM), dropping by 36.47%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 95 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust State Street Spd Put Option (XBI) | 13.0 | $354M | +152% | 2.9M | 121.93 |
|
| Krystal Biotech (KRYS) | 8.6 | $232M | -7% | 941k | 246.54 |
|
| Celcuity (CELC) | 6.7 | $180M | +53% | 1.8M | 99.74 |
|
| Novocure Ord Shs (NVCR) | 4.1 | $110M | -11% | 8.5M | 12.93 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.9 | $107M | -57% | 363k | 294.74 |
|
| Tg Therapeutics (TGTX) | 3.5 | $94M | -18% | 3.1M | 29.81 |
|
| Dex (DXCM) | 3.2 | $86M | NEW | 1.3M | 66.37 |
|
| BioMarin Pharmaceutical (BMRN) | 2.9 | $78M | +48% | 1.3M | 59.43 |
|
| Globus Med Cl A (GMED) | 2.9 | $77M | +403% | 887k | 87.31 |
|
| Beta Bionics (BBNX) | 2.8 | $77M | -34% | 2.5M | 30.47 |
|
| Amicus Therapeutics (FOLD) | 2.7 | $74M | +11% | 5.2M | 14.24 |
|
| Twist Bioscience Corp (TWST) | 2.2 | $59M | 1.9M | 31.72 |
|
|
| Organogenesis Hldgs (ORGO) | 1.9 | $52M | -17% | 10M | 5.18 |
|
| Syndax Pharmaceuticals (SNDX) | 1.7 | $47M | +11% | 2.2M | 21.01 |
|
| Mirum Pharmaceuticals (MIRM) | 1.7 | $45M | +285% | 574k | 78.99 |
|
| Insulet Corporation (PODD) | 1.6 | $43M | NEW | 150k | 284.24 |
|
| Neuropace (NPCE) | 1.5 | $42M | -8% | 2.7M | 15.44 |
|
| Axogen (AXGN) | 1.5 | $40M | -30% | 1.2M | 32.73 |
|
| Biosante Pharmaceuticals (ANIP) | 1.4 | $38M | +42% | 486k | 78.94 |
|
| Alkermes SHS (ALKS) | 1.4 | $37M | NEW | 1.3M | 27.98 |
|
| Livanova SHS (LIVN) | 1.3 | $35M | NEW | 568k | 61.53 |
|
| GSK Sponsored Adr (GSK) | 1.2 | $31M | +190% | 639k | 49.04 |
|
| Geron Corporation (GERN) | 1.1 | $31M | +34% | 23M | 1.32 |
|
| United Therapeutics Corporation (UTHR) | 1.1 | $29M | -60% | 60k | 487.25 |
|
| Immunovant (IMVT) | 1.0 | $28M | NEW | 1.1M | 25.42 |
|
| Vaxcyte (PCVX) | 1.0 | $28M | NEW | 609k | 46.14 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.0 | $28M | +359% | 70k | 397.65 |
|
| Inspire Med Sys (INSP) | 1.0 | $28M | -58% | 299k | 92.23 |
|
| Vericel (VCEL) | 1.0 | $28M | +53% | 764k | 36.01 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.0 | $27M | -54% | 32k | 840.95 |
|
| Rapt Therapeutics Com New (RAPT) | 1.0 | $26M | +42% | 764k | 33.87 |
|
| Neurocrine Biosciences (NBIX) | 0.9 | $25M | +27% | 176k | 141.83 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.9 | $24M | +291% | 587k | 41.25 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.9 | $24M | 7.3M | 3.29 |
|
|
| Teleflex Incorporated (TFX) | 0.9 | $23M | NEW | 190k | 122.04 |
|
| Nurix Therapeutics (NRIX) | 0.9 | $23M | -49% | 1.2M | 18.97 |
|
| Edgewise Therapeutics (EWTX) | 0.8 | $23M | NEW | 910k | 24.82 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.8 | $22M | +71% | 11M | 2.05 |
|
| Pharvaris N V (PHVS) | 0.7 | $20M | +8% | 702k | 27.75 |
|
| Adagio Therapeutics (IVVD) | 0.7 | $19M | NEW | 7.7M | 2.47 |
|
| Capricor Therapeutics Com New (CAPR) | 0.7 | $19M | NEW | 646k | 28.86 |
|
| Tenet Healthcare Corp Com New (THC) | 0.7 | $18M | NEW | 93k | 198.72 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.6 | $17M | NEW | 712k | 23.83 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $16M | NEW | 1.0M | 15.40 |
|
| Mbx Biosciences (MBX) | 0.5 | $13M | +48% | 409k | 31.54 |
|
| Rigel Pharmaceuticals (RIGL) | 0.5 | $13M | -9% | 300k | 42.83 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $12M | 797k | 15.43 |
|
|
| Trevi Therapeutics (TRVI) | 0.4 | $11M | +3500% | 900k | 12.52 |
|
| Sionna Therapeutics (SION) | 0.4 | $11M | -35% | 269k | 41.14 |
|
| Septerna (SEPN) | 0.4 | $11M | +1999% | 383k | 27.88 |
|
| Orthopediatrics Corp. (KIDS) | 0.3 | $9.3M | +310% | 525k | 17.76 |
|
| Terns Pharmaceuticals (TERN) | 0.3 | $8.6M | -97% | 213k | 40.40 |
|
| Cidara Therapeutics Com New (CDTX) | 0.3 | $8.6M | -92% | 39k | 220.89 |
|
| Insmed Com Par $.01 (INSM) | 0.3 | $8.4M | +1801% | 49k | 174.04 |
|
| Cerus Corporation (CERS) | 0.3 | $8.2M | NEW | 4.0M | 2.06 |
|
| Erasca (ERAS) | 0.3 | $8.0M | 2.2M | 3.72 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $8.0M | NEW | 442k | 18.16 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.3 | $7.3M | -46% | 3.8M | 1.91 |
|
| Evolus (EOLS) | 0.3 | $7.1M | -26% | 1.1M | 6.65 |
|
| Cg Oncology (CGON) | 0.3 | $7.1M | -41% | 170k | 41.52 |
|
| Anaptysbio Inc Common (ANAB) | 0.2 | $6.5M | -78% | 135k | 48.48 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.2 | $6.5M | -80% | 40k | 159.96 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $6.3M | NEW | 90k | 69.55 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.2 | $6.1M | NEW | 45k | 134.85 |
|
| Oruka Therapeutics (ORKA) | 0.2 | $5.8M | NEW | 190k | 30.31 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.2 | $5.3M | NEW | 400k | 13.18 |
|
| Neogenomics Com New (NEO) | 0.2 | $5.0M | NEW | 428k | 11.76 |
|
| Natera (NTRA) | 0.2 | $4.6M | NEW | 20k | 229.09 |
|
| Calcimedica Com New (CALC) | 0.2 | $4.5M | 684k | 6.59 |
|
|
| Pulmonx Corp (LUNG) | 0.2 | $4.5M | NEW | 2.0M | 2.21 |
|
| Cogent Biosciences (COGT) | 0.2 | $4.3M | NEW | 120k | 35.52 |
|
| Indivior Ord | 0.1 | $3.6M | -93% | 100k | 35.88 |
|
| Urogen Pharma (URGN) | 0.1 | $3.5M | -77% | 150k | 23.42 |
|
| Tyra Biosciences (TYRA) | 0.1 | $3.3M | NEW | 125k | 26.29 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $3.2M | NEW | 440k | 7.36 |
|
| Zymeworks Del (ZYME) | 0.1 | $2.6M | NEW | 100k | 26.33 |
|
| Viking Therapeutics (VKTX) | 0.1 | $2.5M | NEW | 70k | 35.18 |
|
| Quidel Corp (QDEL) | 0.1 | $2.1M | -80% | 75k | 28.56 |
|
| Inspiremd (NSPR) | 0.1 | $2.0M | -21% | 1.2M | 1.78 |
|
| Inhibrx Biosciences (INBX) | 0.1 | $2.0M | NEW | 25k | 79.00 |
|
| Arcellx Common Stock (ACLX) | 0.1 | $2.0M | -70% | 30k | 65.20 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $1.7M | -88% | 70k | 25.00 |
|
| Bicara Therapeutics (BCAX) | 0.1 | $1.7M | NEW | 100k | 16.83 |
|
| Kodiak Sciences (KOD) | 0.1 | $1.7M | +205% | 60k | 27.96 |
|
| Grail (GRAL) | 0.0 | $942k | NEW | 11k | 85.59 |
|
| Fractyl Health (GUTS) | 0.0 | $880k | -84% | 400k | 2.20 |
|
| Staar Surgical Com Par $0.01 (STAA) | 0.0 | $577k | -95% | 25k | 23.09 |
|
| Veracyte (VCYT) | 0.0 | $421k | -97% | 10k | 42.10 |
|
| Jasper Therapeutics Com New (JSPR) | 0.0 | $366k | -86% | 200k | 1.83 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.0 | $361k | NEW | 25k | 14.43 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.0 | $291k | -99% | 500.00 | 582.34 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.0 | $223k | -97% | 10k | 22.26 |
|
| Dyne Therapeutics (DYN) | 0.0 | $196k | NEW | 10k | 19.56 |
|
| Delcath Sys Com New (DCTH) | 0.0 | $101k | 10k | 10.10 |
|
|
| Tango Therapeutics (TNGX) | 0.0 | $89k | -96% | 10k | 8.86 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2025 Q4 filed Feb. 12, 2026
- Soleus Capital Management 2025 Q3 filed Nov. 14, 2025
- Soleus Capital Management 2025 Q2 filed Aug. 15, 2025
- Soleus Capital Management 2025 Q1 filed May 15, 2025
- Soleus Capital Management 2024 Q4 filed Feb. 14, 2025
- Soleus Capital Management 2024 Q3 filed Nov. 14, 2024
- Soleus Capital Management 2024 Q2 filed Aug. 14, 2024
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022
- Soleus Capital Management 2022 Q1 filed May 16, 2022